By Lina carolina 
Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumours in particular can be difficult to treat surgically. A research team from MedUni Vienna and University Hospital Vienna has now investigated the effectiveness of a new type of therapy and achieved promising results: The active substance TVEC led to a reduction in the size of the basal cell carcinoma in all study participants, which not only improved surgical removal, but also led to a complete regression of the tumour in some of the patients. The study was published in the top journal Nature Cancer.
Breakthrough Gene Therapy Offers New Hope for Difficult-to-Treat Skin Cancers
A groundbreaking study conducted by researchers at MedUni Vienna and University Hospital Vienna has unveiled a novel gene therapy approach demonstrating significant promise in treating locally advanced basal cell carcinoma (BCC), the most prevalent form of skin cancer. The therapy, utilizing Talimogene Laherparepvec (TVEC), has shown an unprecedented ability to shrink tumors, facilitating less invasive surgical procedures and, in some instances, leading to complete tumor eradication. These findings, published in the esteemed journal Nature Cancer, represent a pivotal advancement in the management of a condition that can pose considerable challenges due to its location and severity.
For decades, the primary treatment for BCC has been surgical excision. However, when these tumors become locally advanced, particularly on the face, surgical intervention can be complex, often requiring extensive tissue removal and reconstruction, leading to significant functional and cosmetic impairments. The introduction of TVEC as a neoadjuvant therapy – meaning it is administered before surgery – aims to mitigate these challenges by reducing tumor size and potentially obviating the need for more aggressive surgical techniques.
Understanding Talimogene Laherparepvec (TVEC): A Dual-Action Onolytic and Immunotherapeutic Agent
TVEC, the active substance at the heart of this study, is not a novel entity in the realm of cancer treatment, but its application to BCC is a significant development. Previously, TVEC has been approved for the treatment of superficial melanoma metastases. Its mechanism of action is two-fold: it is a genetically modified herpes simplex virus designed to selectively infect and destroy tumor cells (oncolysis), while simultaneously stimulating the body’s own immune system to recognize and attack cancer.
The virus is engineered to replicate preferentially within tumor cells, leading to their lysis and the release of tumor-associated antigens. This process acts as an in-situ vaccine, priming the immune system, particularly T-cells, to mount a targeted response against the cancer. This dual approach of direct tumor destruction and immune activation is what makes TVEC a compelling candidate for treating various forms of cancer, including those that have historically proven resistant to conventional therapies.
The Clinical Trial: A Chronological Approach to Enhancing Surgical Outcomes
The study enrolled 18 patients who presented with basal cell carcinomas that were deemed too extensive or strategically located to be treated with simple surgical excision without significant disfigurement or loss of function. These individuals would typically have required reconstructive surgery, such as skin grafts or flaps, to close the resulting wound. The treatment protocol involved a series of six intralesional injections of TVEC administered directly into the tumor site over a period of 13 weeks. This pre-operative treatment phase was meticulously designed to shrink the tumors before the planned surgical removal.
The timeline of the study unfolded as follows:
- Initial Assessment and Patient Selection: Patients were identified based on the size and location of their BCC, indicating a need for complex surgical intervention. This selection process was crucial to target individuals who would most benefit from a neoadjuvant therapy aimed at simplifying surgery.
- Treatment Initiation: Commencing the 13-week treatment period, patients received their first of six intralesional TVEC injections. This marked the beginning of the tumor-shrinking and immune-priming phase.
- Ongoing Injections and Monitoring: Over the subsequent weeks, patients underwent further injections at prescribed intervals, allowing for the continuous action of TVEC on the tumor and the developing immune response. Regular monitoring would have been conducted to assess tumor response and any potential side effects.
- Surgical Intervention: Following the completion of the 13-week TVEC regimen, the surgical removal of the treated basal cell carcinomas was performed. The primary objective at this stage was to evaluate the extent of tumor reduction and the feasibility of less invasive surgical techniques.
- Histological Analysis: Post-surgery, tissue samples were subjected to detailed histological examination. This crucial step aimed to determine the presence and viability of remaining tumor cells, providing definitive evidence of treatment efficacy.
- Follow-up and Long-Term Assessment: Although not explicitly detailed in the provided summary, a comprehensive study would include long-term follow-up to monitor for recurrence and assess the durability of the treatment response.
Supporting Data: Quantifiable Reductions and Complete Remissions
The results of the study, as presented by the research team, are highly encouraging and supported by specific quantitative data:
- Tumor Size Reduction: In a significant portion of patients, TVEC treatment led to a demonstrable reduction in tumor size. This reduction was substantial enough in half of the participants to allow for surgical closure of the wound directly, eliminating the need for more complex reconstructive procedures.
- Complete Tumor Regression: In a remarkable one-third of the cases, subsequent histological examination revealed no detectable living tumor cells following TVEC treatment and surgery. This indicates a complete pathological response, a highly desirable outcome in cancer treatment.
- Universal Efficacy in Shrinking Tumors: Importantly, the study reported that all treated tumors experienced a reduction in size. This universal efficacy, even in cases where complete regression was not achieved, underscores the potent anti-tumor activity of TVEC. Furthermore, no tumor growth was observed during the treatment period, indicating effective disease control.
- Immunological Enhancement: Beyond the direct tumor-killing effects, comprehensive analyses, conducted in collaboration with St. Anna Children’s Hospital, revealed a strengthening of the immune defense within the tumor tissue during TVEC therapy. This suggests that the therapy effectively primes the local immune microenvironment for a more robust anti-cancer response.
Official Responses and Expert Commentary
The principal investigator of the study, Christoph Höller, Head of the Skin Tumour Centre at the Department of Dermatology, expressed optimism regarding the findings. "This enabled the tumour to be reduced in size in half of the patients to such an extent that surgery with direct wound closure was possible. In a third of the cases, the subsequent histological examination even showed no more living tumour cells. All treated tumours at least became smaller, and no tumour grew further under the therapy. The treatment was well tolerated by the patients," stated Dr. Höller, summarizing the study’s success. His comments highlight not only the efficacy but also the favorable safety profile of the treatment.
Julia Ressler, the first author of the study and also affiliated with the Department of Dermatology, further elaborated on the clinical implications: "The new treatment option for basal cell carcinoma can not only simplify surgery, but also help to avoid disfiguring operations and functional limitations." This statement emphasizes the patient-centric benefits of the therapy, addressing the significant quality-of-life improvements that can be achieved by minimizing the impact of cancer treatment.
Broader Impact and Future Implications
The implications of this research extend beyond the immediate cohort of patients. The success of TVEC in treating locally advanced BCC opens new avenues for managing this common malignancy. The concept of neoadjuvant therapy in BCC, particularly for tumors that pose a surgical challenge, has been a long-sought goal. This study provides robust evidence that such an approach is not only feasible but highly effective.
Potential for Reduced Surgical Burden: The ability to simplify surgery by reducing tumor size can translate into shorter operating times, reduced hospital stays, and faster recovery periods for patients. This could alleviate pressure on healthcare systems and improve patient outcomes.
Minimizing Disfigurement and Functional Loss: For BCCs located on cosmetically sensitive areas like the face, the prospect of avoiding extensive surgery and the associated disfigurement is a significant breakthrough. Similarly, preserving critical facial structures and functions is paramount, and TVEC’s ability to shrink tumors before intervention could play a crucial role in achieving this.
Expanding the Use of Oncolytic Viruses: This study contributes to the growing body of evidence supporting the role of oncolytic viruses in cancer therapy. The success with BCC, a non-melanoma skin cancer, suggests that TVEC and similar agents could potentially be explored for other types of skin cancers or even other solid tumors.
Foundation for Further Research: The researchers themselves acknowledge the need for further investigation. "Further studies are to follow in order to confirm the benefits of this new option in a larger patient population," the article states. This indicates a commitment to rigorous scientific validation and the development of evidence-based clinical guidelines. Future studies will likely focus on optimizing treatment protocols, identifying patient subgroups that might respond best, and potentially combining TVEC with other therapeutic modalities to further enhance efficacy.
The publication of these findings in Nature Cancer signifies the high impact and scientific rigor of this research. It places TVEC therapy at the forefront of innovative treatments for basal cell carcinoma, offering a beacon of hope for patients facing challenging diagnoses and underscoring the continued evolution of personalized and targeted cancer therapies. The collaborative efforts of MedUni Vienna and University Hospital Vienna, coupled with the multidisciplinary approach involving dermatologists and immunologists, have paved the way for a potentially transformative treatment for a widespread form of cancer.